Management of Ewing sarcoma family of tumors: Current scenario and unmet need

doi:10.5312/wjo.v7.i9.527

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8932)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

779

WORD

468

HTML

4665

Tables (1-4)

232

Sum=6144

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1067

Download

1721

Sum=2788

Sep 18, 2016 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Orthop. Sep 18, 2016; 7(9): 527-538
Published online Sep 18, 2016. doi: 10.5312/wjo.v7.i9.527

Table 2 Euro-Ewing 99 trial design and details

Randomized arm	Patients	n	Randomization	3-yr EFS
Arm 1	SR, Localized (good histologic response, < 200 mL + RT)	856	6#VIDE + 1#VAI f/b 7#VAI vs 7#VAC	78% vs 75%
Arm 2	HR, Localized (poor histologic response, ≥ 200 mL and RT alone)	---	6#VIDE + 1#VAI f/b 7# VAI vs BuMel (n = 281)	45% (BuMel)
	Lung metastasis only	---	6#VIDE + 1#VAI f/b 7# VAI + WLI vs BuMel	---
Arm 3	Extrapulmonary metastasis	---	6#VIDE + 1#VAI f/b BuMel/TreoMel vs clinical trial	---

BuMel: Busulphan and melphalan; EFS: Event free survival; f/b: Followed-by; HR: High risk; n: Number; RT: Radiotherapy; SR: Standard risk; TreoMel: Tresulphan and melphalan; VAC: Vincristine, dactinomycin, cyclophosphamide; VAI: Vincristine, dactinomycin, ifosfamide; VIDE: Vincristine, ifosfamide, doxorubicin, etoposide; WLI: Whole lung irradiation.

Citation: Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors: Current scenario and unmet need. World J Orthop 2016; 7(9): 527-538
URL: https://www.wjgnet.com/2218-5836/full/v7/i9/527.htm
DOI: https://dx.doi.org/10.5312/wjo.v7.i9.527